# US 2023/0069749 A1 · Use of poziotinib for the treatment of cancers with nrg1 fusions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0069749 A1
- Document ID: US20230069749A1
- Status: Published application
- Kind: A1
- Application number: 17/759,713
- Filed: 2021-01-29
- Published: 2023-03-02
- Earliest claimed: 2020-01-29
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, The University of Texas System
- Inventors: John HEYMACH; Jacqulyne ROBICHAUX
- Web page: https://patentgrep.com/patent/US20230069749A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- C07K 16/32: against translation products of oncogenes
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 2039/505: {comprising antibodies}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided herein are methods of selecting cancer patients for treatment with poziotinib as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with poziotinib alone or in combination with HER2/HER3 targeting antibodies.

## Claims

### Claim 1

A method of treating a patient having a cancer, the method comprising administering to the patient a therapeutically effective amount of poziotinib, wherein the cancer has an NRG1 fusion.

### Claim 2

A method of treating a patient having a cancer, the method comprising (a) determining or having determined whether the patient's cancer has an NRG1 fusion; (b) selecting or having selected the patient for treatment with poziotinib when the patient's cancer has an NRG1 fusion; and (c) administering or having administered to the selected patient a therapeutically effective amount of poziotinib.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the NRG1 fusion is an NRG1-DOC4 fusion, an NRG1-VAMP2 fusion, an NRG1-CLU fusion, an NRG1-SLC3A2 fusion, an NRG1-CD74 fusion, an NRG1-ATP1B1 fusion, or an NRG1-SDC4 fusion.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, further comprising administering to the patient an HER2/HER3 targeting antibody.

### Claim 5 (depends on 4)

The method of claim 4, wherein the HER2/HER3 targeting antibody comprises trastuzumab, pertuzumab, or T-DM1.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein step (a) comprises (i) obtaining or having obtained a biological sample from the patient; and (ii) performing or having performed an assay on the biological sample to determine the patient's cancer has an NRG1 fusion.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, further comprising administering a further anti-cancer therapy to the patient.

### Claim 8 (depends on 7)

The method of claim 7, wherein the further anti-cancer therapy is a surgical therapy, a chemotherapy, a radiation therapy, a cryotherapy, a hormonal therapy, a toxin therapy, an immunotherapy, or a cytokine therapy.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the cancer is a breast cancer, a lung cancer, a colorectal cancer, a neuroblastoma, a pancreatic cancer, a brain cancer, a stomach cancer, a skin cancer, a testicular cancer, a prostate cancer, an ovarian cancer, a liver cancer, an esophageal cancer, a cervical cancer, a head and neck cancer, a melanoma, or a glioblastoma.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the cancer is a breast cancer or a lung cancer.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the patient has previously undergone at least one round of anti-cancer therapy.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, further comprising reporting the presence of an NRG1 fusion in the patient's cancer.

### Claim 13 (depends on 12)

The method of claim 12, wherein reporting comprises preparing a written or electronic report.

### Claim 14 (depends on 12, 13)

The method of claim 12 or 13, further comprising providing the report to the subject, a doctor, a hospital, or an insurance company.

### Claim 15

A method of selecting a patient having a cancer for treatment with poziotinib, the method comprising (a) determining or having determined whether the patient's cancer has an NRG1 fusion; (b) selecting or having selected the patient for treatment with poziotinib when the patient's cancer has an NRG1 fusion.

### Claim 16 (depends on 15)

The method of claim 15, wherein step (a) comprises (i) obtaining or having obtained a biological sample from the patient; and (ii) performing or having performed an assay on the biological sample to determine the patient's cancer has an NRG1 fusion.

### Claim 17 (depends on 15, 16)

The method of claim 15 or 16, further comprising (c) administering or having administered to the selected patient a therapeutically effective amount of poziotinib.

### Claim 18 (depends on 15, 16, 17)

The method of any one of claims 15-17, wherein the NRG1 fusion is an NRG1-DOC4 fusion, an NRG1-VAMP2 fusion, an NRG1-CLU fusion, an NRG1-SLC3A2 fusion, an NRG1-CD74 fusion, an NRG1-ATP1B1 fusion, or an NRG1-SDC4 fusion.

### Claim 19 (depends on 17, 18)

The method of claim 17 or 18, further comprising administering to the patient an HER2/HER3 targeting antibody.

### Claim 20 (depends on 19)

The method of claim 19, wherein the HER2/HER3 targeting antibody comprises trastuzumab, pertuzumab, or T-DM1.

### Claim 21 (depends on 17, 18, 19, 20)

The method of any one of claims 17-20, further comprising administering a further anti-cancer therapy to the patient.

### Claim 22 (depends on 21)

The method of claim 21, wherein the further anti-cancer therapy is a surgical therapy, a chemotherapy, a radiation therapy, a cryotherapy, a hormonal therapy, a toxin therapy, an immunotherapy, or a cytokine therapy.

### Claim 23 (depends on 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 15-22, wherein the cancer is a breast cancer, a lung cancer, a colorectal cancer, a neuroblastoma, a pancreatic cancer, a brain cancer, a stomach cancer, a skin cancer, a testicular cancer, a prostate cancer, an ovarian cancer, a liver cancer, an esophageal cancer, a cervical cancer, a head and neck cancer, a melanoma, or a glioblastoma.

### Claim 24 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 15-23, wherein the cancer is a breast cancer or a lung cancer.

### Claim 25 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 15-24, wherein the patient has previously undergone at least one round of anti-cancer therapy.

### Claim 26 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 17-25, further comprising reporting the presence of an NRG1 fusion in the patient's cancer.

### Claim 27 (depends on 26)

The method of claim 26, wherein reporting comprises preparing a written or electronic report.

### Claim 28 (depends on 26, 27)

The method of claim 26 or 27, further comprising providing the report to the subject, a doctor, a hospital, or an insurance company.

### Claim 29

A method of treating a patient having a cancer, the method comprising administering to the patient a combined therapeutically effective amount of poziotinib and a HER2/HER3 targeting antibody, wherein the cancer has an NRG1 fusion.

### Claim 30

A method of treating a patient having a cancer, the method comprising (a) determining or having determined whether the patient's cancer has an NRG1 fusion; (b) selecting or having selected the patient for treatment with poziotinib and a HER2/HER3 targeting antibody when the patient's cancer has an NRG1 fusion; and (c) administering or having administered to the selected patient a combined therapeutically effective amount of poziotinib and HER2/HER3 targeting antibody.

### Claim 31 (depends on 29, 30)

The method of claim 29 or 30, wherein the NRG1 fusion is an NRG1-DOC4 fusion, an NRG1-VAMP2 fusion, an NRG1-CLU fusion, an NRG1-SLC3A2 fusion, an NRG1-CD74 fusion, an NRG1-ATP1B1 fusion, or an NRG1-SDC4 fusion.

### Claim 32 (depends on 29, 30, 31)

The method of any one of claims 29-31, wherein the HER2/HER3 targeting antibody comprises trastuzumab, pertuzumab, or T-DM1.

### Claim 33 (depends on 29, 30, 31, 32)

The method of any one of claims 29-32, wherein step (a) comprises (i) obtaining or having obtained a biological sample from the patient; and (ii) performing or having performed an assay on the biological sample to determine the patient's cancer has an NRG1 fusion.

### Claim 34 (depends on 29, 30, 31, 32, 33)

The method of any one of claims 29-33, further comprising administering a further anti-cancer therapy to the patient.

### Claim 35 (depends on 34)

The method of claim 34, wherein the further anti-cancer therapy is a surgical therapy, a chemotherapy, a radiation therapy, a cryotherapy, a hormonal therapy, a toxin therapy, an immunotherapy, or a cytokine therapy.

### Claim 36 (depends on 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 29-35, wherein the cancer is a breast cancer, a lung cancer, a colorectal cancer, a neuroblastoma, a pancreatic cancer, a brain cancer, a stomach cancer, a skin cancer, a testicular cancer, a prostate cancer, an ovarian cancer, a liver cancer, an esophageal cancer, a cervical cancer, a head and neck cancer, a melanoma, or a glioblastoma.

### Claim 37 (depends on 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 29-36, wherein the cancer is a breast cancer or a lung cancer.

### Claim 38 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 29-37, wherein the patient has previously undergone at least one round of anti-cancer therapy.

### Claim 39 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 29-38, further comprising reporting the presence of an NRG1 fusion in the patient's cancer.

### Claim 40 (depends on 39)

The method of claim 39, wherein reporting comprises preparing a written or electronic report.

### Claim 41 (depends on 39, 40)

The method of claim 39 or 40, further comprising providing the report to the subject, a doctor, a hospital, or an insurance company.

### Claim 42

A method of selecting a patient having a cancer for treatment with poziotinib and HER2/HER3 targeting antibody, the method comprising (a) determining or having determined whether the patient's cancer has an NRG1 fusion; (b) selecting or having selected the patient for treatment with poziotinib and a HER2/HER3 targeting antibody when the patient's cancer has an NRG1 fusion.

### Claim 43 (depends on 42)

The method of claim 42, wherein step (a) comprises (i) obtaining or having obtained a biological sample from the patient; and (ii) performing or having performed an assay on the biological sample to determine the patient's cancer has an NRG1 fusion.

### Claim 44 (depends on 42, 43)

The method of claim 42 or 43, further comprising (c) administering or having administered to the selected patient a combined therapeutically effective amount of poziotinib and a HER2/HER3 targeting antibody.

### Claim 45 (depends on 42, 43, 44)

The method of any one of claims 42-44, wherein the NRG1 fusion is an NRG1-DOC4 fusion, an NRG1-VAMP2 fusion, an NRG1-CLU fusion, an NRG1-SLC3A2 fusion, an NRG1-CD74 fusion, an NRG1-ATP1B1 fusion, or an NRG1-SDC4 fusion.

### Claim 46 (depends on 42, 43, 44, 45)

The method of any one of claims 42-45, wherein the HER2/HER3 targeting antibody comprises trastuzumab, pertuzumab, or T-DM1.

### Claim 47 (depends on 44, 45, 46)

The method of any one of claims 44-46, further comprising administering a further anti-cancer therapy to the patient.

### Claim 48 (depends on 47)

The method of claim 47, wherein the further anti-cancer therapy is a surgical therapy, a chemotherapy, a radiation therapy, a cryotherapy, a hormonal therapy, a toxin therapy, an immunotherapy, or a cytokine therapy.

### Claim 49 (depends on 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 42-48, wherein the cancer is a breast cancer, a lung cancer, a colorectal cancer, a neuroblastoma, a pancreatic cancer, a brain cancer, a stomach cancer, a skin cancer, a testicular cancer, a prostate cancer, an ovarian cancer, a liver cancer, an esophageal cancer, a cervical cancer, a head and neck cancer, a melanoma, or a glioblastoma.

### Claim 50 (depends on 42, 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 42-49, wherein the cancer is a breast cancer or a lung cancer.

### Claim 51 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 42-50, wherein the patient has previously undergone at least one round of anti-cancer therapy.

### Claim 52 (depends on 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 44-51, further comprising reporting the presence of an NRG1 fusion in the patient's cancer.

### Claim 53 (depends on 52)

The method of claim 52, wherein reporting comprises preparing a written or electronic report.

### Claim 54 (depends on 52, 53)

The method of claim 52 or 53, further comprising providing the report to the subject, a doctor, a hospital, or an insurance company.
